Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis

The effectiveness of personalized therapy for rheumatoid arthritis (RA) is associated with the correct choice of the drug and the ability to predict its effect before starting the treatment.Objective: to study in patients with RA the relationship between results of therapy and initial expression of...

Full description

Saved in:
Bibliographic Details
Main Authors: G. A. Markova, E. V. Chetina, A. M. Satybaldyev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2022-10-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1341
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849691530863837184
author G. A. Markova
E. V. Chetina
A. M. Satybaldyev
author_facet G. A. Markova
E. V. Chetina
A. M. Satybaldyev
author_sort G. A. Markova
collection DOAJ
description The effectiveness of personalized therapy for rheumatoid arthritis (RA) is associated with the correct choice of the drug and the ability to predict its effect before starting the treatment.Objective: to study in patients with RA the relationship between results of therapy and initial expression of genes responsible for bone and articular cartilage resorption (matrix metalloproteinase 9 – MMP9, – cathepsin K) and inflammation (tumor necrosis factor α – TNFα – and interleukin 1β – IL1β) in mononuclear cells of peripheral blood (PBMC), cultured with tofacitinib (TOFA).Patients and methods. We examined 12 patients with RA who had not previously received TOFA. The average age of the patients was 51 years, the average duration of the disease was 37.6 months. After 3 months of TOFA therapy, 6 patients achieved remission, while the rest had high and moderate disease activity. PBMC were isolated before therapy using a Ficoll density gradient and cultured in the presence of 100 nM TOFA for 48 h. Total RNA obtained from these cells was used to analyze the expression of MMP9, cathepsin K, IL1β, and TNFα genes using a real-time quantitative reverse transcription polymerase chain reaction.Results and discussion. TOFA is able to modify gene expression in cultured PBMC from RA patients compared to control cells. The initial expression of all the studied genes was significantly increased in cultured with TOFA cells of patients with persistent high and moderate disease activity during therapy, while TNFα gene expression was significantly reduced in patients who achieved remission.Conclusion. In patients with RA who have not previously received TOFA, a decrease in TNFα gene expression in blood cells cultured with this drug before the start of therapy may be a prognostic biomarker for achieving remission during TOFA therapy.
format Article
id doaj-art-bb2a7d79d5cf4afe9b357f860b067bd1
institution DOAJ
issn 1996-7012
2310-158X
language Russian
publishDate 2022-10-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-bb2a7d79d5cf4afe9b357f860b067bd12025-08-20T03:20:59ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2022-10-01165222710.14412/1996-7012-2022-5-22-272513Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritisG. A. Markova0E. V. Chetina1A. M. Satybaldyev2V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyThe effectiveness of personalized therapy for rheumatoid arthritis (RA) is associated with the correct choice of the drug and the ability to predict its effect before starting the treatment.Objective: to study in patients with RA the relationship between results of therapy and initial expression of genes responsible for bone and articular cartilage resorption (matrix metalloproteinase 9 – MMP9, – cathepsin K) and inflammation (tumor necrosis factor α – TNFα – and interleukin 1β – IL1β) in mononuclear cells of peripheral blood (PBMC), cultured with tofacitinib (TOFA).Patients and methods. We examined 12 patients with RA who had not previously received TOFA. The average age of the patients was 51 years, the average duration of the disease was 37.6 months. After 3 months of TOFA therapy, 6 patients achieved remission, while the rest had high and moderate disease activity. PBMC were isolated before therapy using a Ficoll density gradient and cultured in the presence of 100 nM TOFA for 48 h. Total RNA obtained from these cells was used to analyze the expression of MMP9, cathepsin K, IL1β, and TNFα genes using a real-time quantitative reverse transcription polymerase chain reaction.Results and discussion. TOFA is able to modify gene expression in cultured PBMC from RA patients compared to control cells. The initial expression of all the studied genes was significantly increased in cultured with TOFA cells of patients with persistent high and moderate disease activity during therapy, while TNFα gene expression was significantly reduced in patients who achieved remission.Conclusion. In patients with RA who have not previously received TOFA, a decrease in TNFα gene expression in blood cells cultured with this drug before the start of therapy may be a prognostic biomarker for achieving remission during TOFA therapy.https://mrj.ima-press.net/mrj/article/view/1341rheumatoid arthritistofacitinibgene expressioncultured peripheral blood mononuclear cellspredictive biomarkerstumor necrosis factor-α.
spellingShingle G. A. Markova
E. V. Chetina
A. M. Satybaldyev
Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
Современная ревматология
rheumatoid arthritis
tofacitinib
gene expression
cultured peripheral blood mononuclear cells
predictive biomarkers
tumor necrosis factor-α.
title Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
title_full Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
title_fullStr Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
title_full_unstemmed Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
title_short Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
title_sort predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
topic rheumatoid arthritis
tofacitinib
gene expression
cultured peripheral blood mononuclear cells
predictive biomarkers
tumor necrosis factor-α.
url https://mrj.ima-press.net/mrj/article/view/1341
work_keys_str_mv AT gamarkova predictingtheefficacyoftofacitinibtherapybasedongeneexpressionofproinflammatorycytokinesandproteasesinculturedbloodcellsofpatientswithrheumatoidarthritis
AT evchetina predictingtheefficacyoftofacitinibtherapybasedongeneexpressionofproinflammatorycytokinesandproteasesinculturedbloodcellsofpatientswithrheumatoidarthritis
AT amsatybaldyev predictingtheefficacyoftofacitinibtherapybasedongeneexpressionofproinflammatorycytokinesandproteasesinculturedbloodcellsofpatientswithrheumatoidarthritis